Vivex Biomedical, Inc. Receives Level II HCPCS Q-Code for Cygnus™, a Human Amniotic Tissue Allograft

ATLANTA Dec. 20, 2016 /PRNewswire

Vivex Biomedical, Inc. (Vivex) is a biomaterials developer focused on creating treatment options and creative solutions to advance clinical, surgical and therapeutic patient care. It has made significant progress in a short time, bringing together the brightest minds in the scientific community and from the orthopaedic and material science industries. With its focus on continued innovation in next-generation biomaterials, Vivex is creating a new standard in patient care and delivering groundbreaking health products to meet the needs of a diverse, rapidly expanding market.

“Vivex is very excited to receive this unique Level II HCPCS Q-Code for Cygnus, one of our premiere amniotic tissue allografts,” commented Michele Pablos, Vice President of Sales and Marketing. “Our goal is to make our products more affordable based on the operating needs of all payers, and this is a huge step in making that goal a reality.”

“Cygnus, an amniotic tissue matrix with innate regenerative capability to support healing, is a product that is available in multiple sizes for multiple uses. Cygnus’ amnion patch is an immune-privileged tissue with proven clinical success in regenerative healing, and we look forward to providing more payers with the opportunity to use it.”

This Q-code set is available for use by an array of payers, and is maintained by the Centers for Medicare and Medicaid Services (CMS).

About Vivex Biomedical, Inc., Powered by UMTB:

Vivex Biomedical, Inc. is a regenerative biologics company, dedicated to creating new standards in patient care. Since 2014, Vivex and UMTB (founded 1970) have strived for methods to translate creative collaborations into treatments for real problems.

In collaboration with multiple partners, Vivex is on the cutting edge of scientific development. Translating innovation into treatments for real problems further expands surgical options. All research and development is focused on making strides in the field of musculoskeletal regenerative medicine, with major areas of investigation including: cartilage, bone, and skin. Innovative vision provides a platform that assists in the regeneration of all these tissue types in a personalized but scalable transplantation model.

Vivex is constantly working closely with services that support the advancement of allograft transplantation, specifically services that are committed to providing care and compassion to donor families while inspiring communities to share life by donating. Partnering with others ensures that families are offered the appropriate options and support for donation, including Life Alliance, the Lions Eye Bank, Brain Bank, and Medical Examiners.



Drue is Managing Partner for The De Angelis Group.

Related Articles

Back to top button